(9th October, 2014); Medpro Pharmaceutica (Pty) Ltd - a subsidiary company of Cipla Medpro, the third largest pharmaceutical company in South Africa , yesterday announced that it has entered into a collaboration with Teva Pharmaceuticals (Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teva) - the largest generic pharmaceutical manufacturer in the world with a presence in about 60 countries and approximately 45,000 dedicated employees worldwide. The collaboration is restricted to the territory of South Africa.
The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva’s broad pharmaceutical product portfolio in South Africa.
“This collaboration is highly complementary and aligns strongly with our philosophy of providing South Africans with access to a broader range of affordable medicines,” says Paul Miller, Chief Executive Officer of Cipla Medpro.
The collaboration with Teva in South Africa will focus on the following therapeutic areas: oncology, central nervous system, women’s health, cardiovascular, ophthalmology and other specialty products.
“Cipla believes that the collaboration with Teva reaffirms its commitment to advancing healthcare for all South Africans,” concludes Subhanu Saxena , Managing Director and Global Chief Executive Officer of Cipla Limited.
The collaboration is subject to approval by the Competition Commission of South Africa.
